Filing Details

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

Edesa Biotech, Inc.

 

(Name of Issuer)

 

Common Stock, no par value per share

 

(Title of Class of Securities)

 

27966L306

 

(CUSIP Number)

 

May 30, 2024

 

 

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

	¨	Rule 13d-1(b)
	x	Rule 13d-1(c)
	¨	Rule 13d-1(d)

 

 

^*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 27966L306

13G

 

1.

NAMES OF REPORTING PERSONS

 

Thomas A. Satterfield, Jr.

 

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

	(a)	¨
	(b)	¨

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

SOLE VOTING POWER

 

38,000

 

6.

SHARED VOTING POWER

 

138,044

 

7.

SOLE DISPOSITIVE POWER

 

38,000

 

8.

SHARED DISPOSITIVE POWER

 

138,044

 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

176,044

 

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

¨

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

5.47%*

 

12.

TYPE OF REPORTING PERSON

 

IN

 

 

* Based on 3,215,968 shares of common stock of the issuer outstanding as of May 10, 2024, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024.

 

 

CUSIP No. 27966L306

13G

 

SCHEDULE 13G

Item 1.

 

(a)

Name of Issuer:

 

Edesa Biotech, Inc.

 

(b)

Address of Issuer's Principal Executive Offices:

 

100 Spy Court

Markham, Ontario, Canada L3R 5H6

 

Item 2.

 

(a)

Name of Person Filing:

 

Thomas A. Satterfield, Jr.

 

(b)

Address of Principal Business Office or, if none, Residence:

 

Thomas A. Satterfield, Jr.

15 Colley Cove Drive

Gulf Breeze, Florida 32561

 

(c)

Citizenship:

 

Incorporated by reference from Item 4 of the Cover Page.

 

(d)

Title of Class of Securities:

 

Incorporated by reference from the Cover Page.

 

(e)

CUSIP Number:

 

Incorporated by reference from the Cover Page.

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

 

Not Applicable.

 

Item 4.

Ownership.

 

(a)

Amount beneficially owned:

 

Incorporated by reference from Item 9 of the Cover Page.

 

(b)

Percent of class:

 

Incorporated by reference from Item 11 of the Cover Page.

 

 

CUSIP No. 27966L306

13G

 

(c)

Number of shares as to which such person has:

 

(i)

Sole power to vote or to direct the vote

 

Incorporated by reference from Item 5 of the Cover Pages.

 

(ii)

Shared power to vote or to direct the vote

 

Incorporated by reference from Item 6 of the Cover Pages.

 

(iii)

Sole power to dispose or to direct the disposition of

 

Incorporated by reference from Item 7 of the Cover Pages.

 

(iv)

Shared power to dispose or to direct the disposition of

 

Incorporated by reference from Item 8 of the Cover Pages.

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 28,348 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 80,000 shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; and 21,696 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield.

 

Additionally, Mr. Satterfield has a limited power of attorney for voting and disposition purposes with respect to the following shares: Rebecca A. Satterfield (8,000 shares). Ms. Satterfield has the right to receive or the power to direct the receipt of the proceeds from the sale of her shares.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not Applicable.

 

Item 10.

Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

CUSIP No. 27966L306

13G

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

	June 3, 2024
	Date
	/s/ Thomas A. Satterfield, Jr.
	Thomas A. Satterfield, Jr.